Chen Yung-Husan, Zhu Qiaoqiao, Li Jingyi, Yang Rong, Zhang Jingwen, You Minxin, Luo Lianzhong, Yang Bingye
Xiamen Key Laboratory of Natural Products Resources of Marine Medicine, Xiamen Medical College, Xiamen 361023, China.
Fujian Provincial University Marine Biomedical Resources Engineering Research Center, Xiamen Medical College, Xiamen 361023, China.
Metabolites. 2024 Jan 31;14(2):99. doi: 10.3390/metabo14020099.
A novel ceramide compound, named Aspercerebroside A (AcA), was successfully isolated from the ethyl acetate layer of the marine symbiotic fungus sp. AcA exhibited notable anti-inflammatory activity by effectively inhibiting the production of nitric oxide (NO) in RAW 264.7 cells at concentrations of 30 μg/mL and 40 μg/mL, offering a promising avenue for the treatment of inflammatory diseases. To optimize the yield of glycosylceramide (AcA), a series of techniques, including single-factor experiments, orthogonal experiments, and response surface optimization, were systematically employed to fine-tune the composition of the fermentation medium. Initially, the optimal carbon source (sucrose), nitrogen source (yeast extract powder), and the most suitable medium salinity (14 ppt) were identified through single-factor experiments. Subsequently, orthogonal experiments, employing an orthogonal table for planning and analyzing multifactor experiments, were conducted. Finally, a mathematical model, established using a Box-Behnken design, comprehensively analyzed the interactions between the various factors to determine the optimal composition of the fermentation medium. According to the model's prediction, when the sucrose concentration was set at 37.47 g/L, yeast extract powder concentration at 19.66 g/L, and medium salinity at 13.31 ppt, the predicted concentration of glycosylceramide was 171.084 μg/mL. The experimental results confirmed the model's accuracy, with the actual average concentration of glycosylceramide under these conditions measured at 171.670 μg/mL, aligning closely with the predicted value.
一种名为曲霉脑苷脂A(AcA)的新型神经酰胺化合物成功地从海洋共生真菌的乙酸乙酯层中分离出来。AcA在30μg/mL和40μg/mL浓度下能有效抑制RAW 264.7细胞中一氧化氮(NO)的产生,表现出显著的抗炎活性,为炎症性疾病的治疗提供了一条有前景的途径。为了优化糖基神经酰胺(AcA)的产量,系统地采用了一系列技术,包括单因素实验、正交实验和响应面优化,以微调发酵培养基的成分。最初,通过单因素实验确定了最佳碳源(蔗糖)、氮源(酵母提取物粉末)和最合适的培养基盐度(14ppt)。随后,进行了正交实验,使用正交表来规划和分析多因素实验。最后,利用Box-Behnken设计建立了一个数学模型,全面分析了各种因素之间的相互作用,以确定发酵培养基的最佳组成。根据该模型的预测,当蔗糖浓度设定为37.47g/L、酵母提取物粉末浓度为19.66g/L、培养基盐度为13.31ppt时,糖基神经酰胺的预测浓度为171.084μg/mL。实验结果证实了该模型的准确性,在这些条件下糖基神经酰胺的实际平均浓度为171.670μg/mL,与预测值非常接近。